AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10430979 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril therapy
Number of subjects: 108
Study 8954432 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 170
Study 8954432 — intervention group
Group type: COMPARATOR
Intervention: Adhesive skin tapes (Control)
Number of subjects: 170
Study 1819777 — intervention group
Group type: EXPERIMENTAL
Intervention: CT and thymostimulin Serono (group A)
Number of subjects: 85
Study 1819777 — intervention group
Group type: COMPARATOR
Intervention: CT alone (group B)
Number of subjects: 85
Study 6214237 — intervention group
Group type: EXPERIMENTAL
Intervention: dexamethasonephosphate
Number of subjects: 100
Study 6214237 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 31371115 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised iloprost
Number of subjects: 16
Study 31371115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29497500 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria rapid diagnostic tests intervention
Number of subjects: 70
Study 27119600 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisia extract (AE)
Number of subjects: 0
Study 27119600 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PO)
Number of subjects: 0
Study 24392793 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic supportive-expressive psychotherapy (SET)
Number of subjects: 153
Study 24392793 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication (ADM)
Number of subjects: 153
Study 24392793 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + clinical management
Number of subjects: 153
Study 22368219 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous aerobic exercise intervention (EX) (6 d/wk, 60 min/d, 60% to 85% max. heart rate)
Number of subjects: 202
Study 22368219 — intervention group
Group type: COMPARATOR
Intervention: Usual lifestyle control (CON)
Number of subjects: 202
Study 22368219 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous aerobic exercise intervention (EX)
Number of subjects: 202
Study 20585102 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 40
Study 17369808 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (3 sessions per week for 8 weeks, running at 75-80% of HR(max))
Number of subjects: 20
Study 17369808 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 20
Study 17369808 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 15752252 — intervention group
Group type: EXPERIMENTAL
Intervention: Reservoir biteguard
Number of subjects: 86
Study 15752252 — intervention group
Group type: COMPARATOR
Intervention: Conventional biteguard
Number of subjects: 86
Study 12193097 — intervention group
Group type: EXPERIMENTAL
Intervention: Darusentan (30, 100, 300 mg/day)
Number of subjects: 142
Study 12193097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 9860785 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinaprilat 1.6 microg/min
Number of subjects: 30
Study 9860785 — intervention group
Group type: COMPARATOR
Intervention: Enalaprilat 5 microg/min
Number of subjects: 30
Study 8130044 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation anaesthesia with isoflurane and nitrous oxide (group 1)
Number of subjects: 20
Study 8130044 — intervention group
Group type: EXPERIMENTAL
Intervention: Total i.v. anaesthesia with alfentanil and propofol (group 2)
Number of subjects: 20
Study 2782246 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual isosorbide dinitrate (ISDN) in Group C (without sustained ISDN therapy)
Number of subjects: 24
Study 2782246 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual isosorbide dinitrate (ISDN) in Group N (with sustained ISDN therapy)
Number of subjects: 24
Study 4471965 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 77
Study 4471965 — intervention group
Group type: COMPARATOR
Intervention: Tubocurarine (tbc)
Number of subjects: 77
Study 4471965 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 77
Study 30793465 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 7637
Study 30793465 — intervention group
Group type: COMPARATOR
Intervention: No liraglutide
Number of subjects: 7637
Study 27038191 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified EMDR procedure with eye movements (n = 24)
Number of subjects: 47
Study 27038191 — intervention group
Group type: COMPARATOR
Intervention: Control group with fixed gaze (n = 23)
Number of subjects: 47
Study 24402203 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Oddball task
Number of subjects: 0
Study 24402203 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory task
Number of subjects: 0
Study 24402203 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory task with high load
Number of subjects: 0
Study 24402203 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory task with low load
Number of subjects: 0
Study 22901904 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondrainage group (n = 60)
Number of subjects: 121
Study 22901904 — intervention group
Group type: COMPARATOR
Intervention: Drainage group (n = 61)
Number of subjects: 121
Study 22901904 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 121
Study 19884365 — intervention group
Group type: EXPERIMENTAL
Intervention: S/GSK1349572 10 mg
Number of subjects: 60
Study 19884365 — intervention group
Group type: EXPERIMENTAL
Intervention: S/GSK1349572 50 mg
Number of subjects: 60
Study 19884365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17828144 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% drops
Number of subjects: 105
Study 17828144 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.75% drops
Number of subjects: 105
Study 17828144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1% drops
Number of subjects: 105
Study 17077653 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication group (n = 27)
Number of subjects: 50
Study 17077653 — intervention group
Group type: COMPARATOR
Intervention: Observation group (n = 23)
Number of subjects: 50
Study 12809357 — intervention group
Group type: EXPERIMENTAL
Intervention: ImmunoGuard (4 mg Andrographolide per tablet, 48 mg daily, taken 3 times of 4 tablets daily for 1 month)
Number of subjects: 24
Study 12809357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11135797 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticultural and nutrition education intervention in the experimental area (Ilongero)
Number of subjects: 236
Study 11135797 — intervention group
Group type: COMPARATOR
Intervention: Experimental area (Ilongero)
Number of subjects: 236
Study 11135797 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with helminths
Number of subjects: 236
Study 8637448 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose (0.2 mg tablet before each test meal, 3 tablets per day)
Number of subjects: 16
Study 7936386 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue (leuprolide acetate depot)
Number of subjects: 30
Study 7936386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2452175 — intervention group
Group type: EXPERIMENTAL
Intervention: New biochemical method for assessing tissue damage via urinary excretion of hypoxanthine.
Number of subjects: 26
Study 30912414 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 48
Study 28326950 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% lidocaine medicated plaster
Number of subjects: 63
Study 28326950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 26265119 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal granisetron (GTDS) - one GTDS patch for 7 days
Number of subjects: 196
Study 26265119 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron - iv 0.25 mg/day for 1 day
Number of subjects: 196
Study 26265119 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal granisetron (GTDS)
Number of subjects: 196
Study 26265119 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron
Number of subjects: 196
Study 23646838 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF)
Number of subjects: 263
Study 23646838 — intervention group
Group type: COMPARATOR
Intervention: Control condition (information about sun protection)
Number of subjects: 263
Study 21946476 — intervention group
Group type: EXPERIMENTAL
Intervention: GuttaFlow
Number of subjects: 80
Study 21946476 — intervention group
Group type: EXPERIMENTAL
Intervention: GuttaFlow and accessory gutta‐percha cones without lateral condensation
Number of subjects: 80
Study 21946476 — intervention group
Group type: COMPARATOR
Intervention: Cold lateral condensation technique
Number of subjects: 80
Study 21946476 — intervention group
Group type: COMPARATOR
Intervention: Continuous wave condensation technique
Number of subjects: 80
Study 19846693 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated weightbearing group (group A)
Number of subjects: 31
Study 19846693 — intervention group
Group type: COMPARATOR
Intervention: Delayed weightbearing group (group B)
Number of subjects: 31
Study 16735938 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 0.05 mg/day
Number of subjects: 52
Study 16735938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 15592280 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene therapy (60 mg/d every other day for 2 months followed by 60 mg/d)
Number of subjects: 487
Study 15592280 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene therapy
Number of subjects: 487
Study 15592280 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-dose escalation of raloxifene therapy
Number of subjects: 487
Study 15592280 — intervention group
Group type: COMPARATOR
Intervention: Phytohormones or veralipride
Number of subjects: 487
Study 11452323 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand washing prior to patient physical examination (PPE)
Number of subjects: 100
Study 11452323 — intervention group
Group type: COMPARATOR
Intervention: No hand washing prior to patient physical examination (PPE)
Number of subjects: 100
Study 9119098 — intervention group
Group type: EXPERIMENTAL
Intervention: Axilloscopy
Number of subjects: 40
Study 9119098 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 40
Study 1648142 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV (cyclophosphamide 800 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine 1.4 mg/m2 IV on day 1)
Number of subjects: 288
Study 1648142 — intervention group
Group type: COMPARATOR
Intervention: PE (cisplatin 80 mg/m2 IV on day 1, etoposide 100 mg/m2 IV on days 1, 3, and 5)
Number of subjects: 288
Study 1648142 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV/PE (alternating CAV and PE)
Number of subjects: 288
Study 6499602 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone metasulphobenzoate enemas
Number of subjects: 0
Study 6499602 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oral prednisolone
Number of subjects: 0
Study 30945320 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 120
Study 30945320 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 120
Study 30945320 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 120
Study 30945320 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 120
Study 30119145 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural levobupivacaine and morphine before incision (Group 1)
Number of subjects: 45
Study 30119145 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural levobupivacaine and morphine after incision (Group 2)
Number of subjects: 45
Study 30119145 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural levobupivacaine and morphine at the end of surgery (Group 3)
Number of subjects: 45
Study 26150037 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmakinetic urethrotomy
Number of subjects: 60
Study 26150037 — intervention group
Group type: COMPARATOR
Intervention: Cold knife urethrotomy
Number of subjects: 60
Study 24183364 — intervention group
Group type: EXPERIMENTAL
Intervention: TA-ER (tramadol hydrochloride 75-mg/acetaminophen 650-mg)
Number of subjects: 245
Study 24183364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 21512394 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored irinotecan and S‐1 therapy (arm A)
Number of subjects: 95
Study 21512394 — intervention group
Group type: COMPARATOR
Intervention: S‐1 monotherapy (arm B)
Number of subjects: 95
Study 19842458 — intervention group
Group type: EXPERIMENTAL
Intervention: ALED-I intervention (16-week Internet-delivered Active Living Every Day program)
Number of subjects: 32
Study 19842458 — intervention group
Group type: COMPARATOR
Intervention: Control crossover participants
Number of subjects: 32
Study 19842458 — intervention group
Group type: EXPERIMENTAL
Intervention: ALED-I intervention (8 months follow-up)
Number of subjects: 32
Study 17714197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sight of chocolate in chocolate cravers
Number of subjects: 0
Study 17714197 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of picture of chocolate with chocolate in the mouth in cravers
Number of subjects: 0
Study 17714197 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasantness ratings of chocolate and chocolate-related stimuli in cravers
Number of subjects: 0
Study 14647957 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0.038 mg/kg)
Number of subjects: 28
Study 14647957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11440835 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-coated dialyzer (VE)
Number of subjects: 16
Study 11440835 — intervention group
Group type: COMPARATOR
Intervention: High biocompatible synthetic dialyzer (AN)
Number of subjects: 16
Study 9764132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention programme
Number of subjects: 0
Study 9764132 — intervention group
Group type: COMPARATOR
Intervention: Control (follow-up study)
Number of subjects: 0
Study 8961074 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril 7.5 mg once daily, increased to 15 mg once daily after 6 weeks if SDBP > 90 mm Hg
Number of subjects: 0
Study 8961074 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg twice daily, increased to 50 mg twice daily after 6 weeks if SDBP > 90 mm Hg
Number of subjects: 0
Study 8961074 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril
Number of subjects: 0
Study 8961074 — intervention group
Group type: COMPARATOR
Intervention: Moexipril and Captopril
Number of subjects: 0
Study 2509064 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 22
Study 2509064 — intervention group
Group type: COMPARATOR
Intervention: Partial parenteral plus enteral nutrition by tube feeding (PPN/EN)
Number of subjects: 22
Study 2509064 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TPN and PPN/EN
Number of subjects: 22
Study 786349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 113
Study 786349 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoperidine
Number of subjects: 113
Study 786349 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 113
Study 786349 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 113
Study 30995970 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral lenses with Dk/t of 100 Barrer
Number of subjects: 10
Study 30995970 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral lenses with Dk/t of 140 Barrer
Number of subjects: 10
Study 30995970 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral lenses with Dk/t of 160 Barrer
Number of subjects: 10
Study 30995970 — intervention group
Group type: EXPERIMENTAL
Intervention: Patched eyes
Number of subjects: 10
Study 30995970 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpatched eyes
Number of subjects: 10
Study 28107763 — intervention group
Group type: EXPERIMENTAL
Intervention: I-SCAN
Number of subjects: 61
Study 28107763 — intervention group
Group type: COMPARATOR
Intervention: HD-WLE
Number of subjects: 61
Study 28107763 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspection time
Number of subjects: 61
Study 26077768 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially defatted Brazil nut flour (13 g/day providing 227.5 μg of selenium/day)
Number of subjects: 77
Study 26077768 — intervention group
Group type: COMPARATOR
Intervention: Dyed cassava flour (placebo)
Number of subjects: 77
Study 23161895 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced alerts with patient's most recent potassium and creatinine levels
Number of subjects: 1029
Study 23161895 — intervention group
Group type: COMPARATOR
Intervention: Unmodified alerts
Number of subjects: 1029
Study 21663428 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (OROS MPH) 18, 36, and 54 mg QD after high-fat breakfast
Number of subjects: 32
Study 21663428 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (OROS MPH) 18, 36, and 54 mg QD after normal breakfast
Number of subjects: 32
Study 21663428 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release methylphenidate (IR MPH) 5, 10, and 15 mg TID after normal breakfast
Number of subjects: 32
Study 21663428 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release methylphenidate (IR MPH) 5, 10, and 15 mg TID after fasting
Number of subjects: 32
Study 19239703 — intervention group
Group type: EXPERIMENTAL
Intervention: Decremental PEEP titration after ARM
Number of subjects: 57
Study 19239703 — intervention group
Group type: COMPARATOR
Intervention: Table-based PEEP (control)
Number of subjects: 57
Study 16107868 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum constriction device (VCD) used daily for 9 months (Group 1, N=74)
Number of subjects: 109
Study 16107868 — intervention group
Group type: COMPARATOR
Intervention: Observation without any erectogenic treatment (Group 2, N=35)
Number of subjects: 109
Study 16107868 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful users of VCD (60 patients)
Number of subjects: 109
Study 16107868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders to VCD (14 patients)
Number of subjects: 109
Study 16107868 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2, N=35)
Number of subjects: 109
Study 15204157 — intervention group
Group type: EXPERIMENTAL
Intervention: ELA-Max (4% liposomal lidocaine)
Number of subjects: 0
Study 15204157 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream (eutectic mixture of local anesthetics)
Number of subjects: 0
Study 11075988 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral formula
Number of subjects: 212
Study 11075988 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition (enteral formula enriched with arginine, omega‐3 fatty acids, and RNA)
Number of subjects: 212
Study 11075988 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 212
Study 11075988 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Number of subjects: 212
Study 9288457 — intervention group
Group type: COMPARATOR
Intervention: Conventional, thin, 38% water, pHEMA soft contact lens (SCL)
Number of subjects: 6
Study 9288457 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental high Dk (EHD), 20%-water soft contact lens
Number of subjects: 6
Study 9288457 — intervention group
Group type: COMPARATOR
Intervention: No contact lens wear
Number of subjects: 6
Study 8312148 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical agents for cutaneous infections in immunocompetent patients
Number of subjects: 0
Study 8312148 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy for recurrent vulvovaginal candidiasis and oroesophageal candida infections
Number of subjects: 0
Study 3552359 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitang (250, 500, and 1000 mg single oral doses)
Number of subjects: 87
Study 3552359 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitang (additional treatment alongside original medications)
Number of subjects: 87
Study 3552359 — intervention group
Group type: COMPARATOR
Intervention: Control group (original medications only)
Number of subjects: 87
Study 31948736 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia module (MM)
Number of subjects: 35
Study 31948736 — intervention group
Group type: COMPARATOR
Intervention: Handout (HO)
Number of subjects: 35
Study 31948736 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HO and MM
Number of subjects: 35
Study 29230716 — intervention group
Group type: EXPERIMENTAL
Intervention: Visnadine spray (ReFeel® spray), 2 puffs in the vulvar area, 10 minutes before sexual stimulation, for 30 days (n=30)
Number of subjects: 60
Study 29230716 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL), 2 puffs in the vulvar area, 10 minutes before sexual stimulation, for 30 days (n=28)
Number of subjects: 60
Study 27506667 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg vitamin D3
Number of subjects: 251
Study 27506667 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg vitamin D3
Number of subjects: 251
Study 27506667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 24785854 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous use of oral contraceptive pills (OCPs)
Number of subjects: 358
Study 24785854 — intervention group
Group type: COMPARATOR
Intervention: Cyclic use of oral contraceptive pills (OCPs)
Number of subjects: 358
Study 22343992 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 30
Study 22343992 — intervention group
Group type: COMPARATOR
Intervention: Control (Group B)
Number of subjects: 30
Study 19594305 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg
Number of subjects: 102
Study 19594305 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 40 microg
Number of subjects: 102
Study 19594305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102